Shire price target raised to $205 from $180 at Jefferies Jefferies raised its price target for Shire shares to $205 citing the company's strong results and its new ADHD candidate. The firm keeps a Buy rating on the stock
Shire receives 'positive opinion' on Intuniv from CHMP Shire announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of the once-daily, non-stimulant Intuniv, or guanfacine hydrochloride extended release, for the treatment of attention deficit/hyperactivity disorder in children and adolescents. The positive opinion is based on results from three Phase 3 pivotal studies investigating the short- and long-term safety and efficacy of Intuniv in children and adolescents. The European Commission will now consider the CHMP positive opinion in its decision of whether to grant marketing authorisation for Intuniv in Europe, said Shire.